Oncology Biosimilars Global Market Report 2022 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : February 2022 | SKU CODE : 7619 | Delivery Time: 2-3 business days | Format :


The oncology biosimilars market consists of sales of medicine and drug related products for cancer treatment. Biosimilars are pharmaceuticals which are manufactured using cell lines and are exclusive to the manufacturer. The manufacturing of these cell line processes is a complex and time-consuming process.

The main drug types of oncology biosimilars are monoclonal antibody, immunomodulators, hematopoietic agents and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, others and the various distribution channel involved are hospital pharmacy, retail pharmacy and online pharmacy.

The global oncology biosimilars market size is expected to grow from $3.27 billion in 2021 to $4.19 billion in 2022 at a compound annual growth rate (CAGR) of 28.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oncology biosimilars market is expected to reach $11.35 billion in 2026 at a CAGR of 28.3%.

The expiration of patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms which induces the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offers the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.

The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, lack of detailed awareness on the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns included safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians and specialists restricts the growth of the oncology biosimilars market.

The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting growth potential of rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus' plan is to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up R&D facility to boost biosimilar development.

Major players in the oncology biosimilars market are Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan and F Hoffmann-La Roche.

North America was the largest region in the oncology biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global oncology biosimilars market is segmented -

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Others

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

    Table Of Contents

    1. Executive Summary

    2. Oncology Biosimilars Market Characteristics

    3. Oncology Biosimilars Market Trends And Strategies

    4. Impact Of COVID-19 On Oncology Biosimilars

    5. Oncology Biosimilars Market Size And Growth

    5.1. Global Oncology Biosimilars Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Oncology Biosimilars Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Oncology Biosimilars Market Segmentation

    6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Monoclonal Antibody

    Immunomodulators

    Hematopoietic Agents

    Granulocyte Colony-Stimulating Factor (G-CSF)

    6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Breast Cancer

    Colorectal Cancer

    Blood Cancer

    Neutropenia Cancer

    Non-Small Cell Lung Cancer

    Others

    6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    7. Oncology Biosimilars Market Regional And Country Analysis

    7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Oncology Biosimilars Market

    8.1. Asia-Pacific Oncology Biosimilars Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Oncology Biosimilars Market

    9.1. China Oncology Biosimilars Market Overview

    9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Oncology Biosimilars Market

    10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Oncology Biosimilars Market

    11.1. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Oncology Biosimilars Market

    12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Oncology Biosimilars Market

    13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Oncology Biosimilars Market

    14.1. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Oncology Biosimilars Market

    15.1. Western Europe Oncology Biosimilars Market Overview

    15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Oncology Biosimilars Market

    16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Oncology Biosimilars Market

    17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Oncology Biosimilars Market

    18.3. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Oncology Biosimilars Market

    19.1. Eastern Europe Oncology Biosimilars Market Overview

    19.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Oncology Biosimilars Market

    20.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Oncology Biosimilars Market

    21.1. North America Oncology Biosimilars Market Overview

    21.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Oncology Biosimilars Market

    22.1. USA Oncology Biosimilars Market Overview

    22.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Oncology Biosimilars Market

    23.1. South America Oncology Biosimilars Market Overview

    23.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Oncology Biosimilars Market

    24.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Oncology Biosimilars Market

    25.1. Middle East Oncology Biosimilars Market Overview

    25.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Oncology Biosimilars Market

    26.1. Africa Oncology Biosimilars Market Overview

    26.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Oncology Biosimilars Market Competitive Landscape And Company Profiles

    27.1. Oncology Biosimilars Market Competitive Landscape

    27.2. Oncology Biosimilars Market Company Profiles

    27.2.1. Biocoin

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Celltrion Inc.

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Dr. Reddy's Laboratories Ltd.

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Intas Pharmaceuticals Ltd.

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. STADA Arzneimittel AG

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Oncology Biosimilars Pipeline Analysis

    29. Key Mergers And Acquisitions In The Oncology Biosimilars Market

    30. Oncology Biosimilars Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Biocoin Financial Performance
  • Figure 28: Celltrion Inc. Financial Performance
  • Figure 29: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Figure 30: Intas Pharmaceuticals Ltd. Financial Performance
  • Figure 31: STADA Arzneimittel AG Financial Performance

List Of Figures

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Biocoin Financial Performance
  • Table 28: Celltrion Inc. Financial Performance
  • Table 29: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Table 30: Intas Pharmaceuticals Ltd. Financial Performance
  • Table 31: STADA Arzneimittel AG Financial Performance
Global Heparin Market Size, Forecasts, And Opportunities – Includes Heparin Market Report
Global Generic Pharmaceuticals Market Outlook, Opportunities And Strategies – Includes Generic Pharmaceuticals Market Size
Global Hormonal Contraceptives Market Outlook, Opportunities And Strategies – Includes Hormonal Contraceptives Market Size
Global Immuno-Oncology Drugs Market Size, Forecasts, And Opportunities – Includes Immuno-Oncology Drugs Market Trends
Global Biosimilars Market Outlook, Opportunities And Strategies – Includes Biosimilars Vs Generic
Global Cancer Monoclonal Antibodies Market Size, Forecasts, And Opportunities – Includes Cancer Monoclonal Antibodies Market Share
Global Coronavirus (COVID-19) Current Therapy Market Outlook, Opportunities And Strategies – Includes Coronavirus (COVID-19) Current Therapy Market Analysis
Global Autoimmune Disease Diagnosis Market Size, Forecasts, And Opportunities – Includes Autoimmune Disease Diagnosis Market Analysis
Oncology Devices Global Market Report 2022 – By Device Type (Brachytherapy Devices, Endoscopic Devices), By Therapy (Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radition Therapy), By End User (Hospitals, Cancer Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Oncology Molecular Diagnostics Global Market Report 2022 – By Product (Instruments, Reagents), By Technology (Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA)), By End User (Hospitals, Diagnostic Centers, Academic & Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Colorectal Cancer Drugs Global Market Report 2022 – By Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies), By Class (Immunotherapy, Chemotherapy) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Oncology Drugs Global Market Report 2022 – By Type (Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Bi-Specific MAbS Global Market Report 2022 – By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Product Type (In Vivo, In Vitro), By Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases), By End Use (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biosimilars Global Market Report 2022 – By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026
View Report
G-CSF (Granulocyte Colony Stimulating Factors) Market 2021 - By Type (Pegfilgrastim, Filgrastim, Lenograstim), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report